TrialEuropean journal of haematology2022

Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.

Austin G Kulasekararaj et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.